FVC · children and young adults with CF
1 finding from 1 review
Intervention not reported
12MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
3MSC: change in 3MSC rates (stairs/min) from baseline · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
6MWT: change from baseline in m walked · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Respiratory tests: absolute change from baseline in FVC (L) · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
Cardiac function  · children and adults with mucopolysaccharidosis type VI
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
GAG level: change in urinary GAG level from baseline ųg/mg creatinine · children and adults with mucopolysaccharidosis type VI
1 finding from 1 review
Intervention not reported
AEs: drug‐related AEs · children and adults with mucopolysaccharidosis type VI
It is very uncertain whether the intervention changes AEs: drug‐related AEs (very low certainty).
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Number of days on antibiotics for acute exacerbations · adults and children with cystic fibrosis
Summary of findings: β‐carotene showed no clear difference in pulmonary exacerbations Days of antibiotic use compared with placebo (low certainty).
1 finding from 1 review
Adverse events mild adverse events · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
1 finding from 1 review
Need for antibiotics days of antibiotic use · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum microbiology · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inflammatory markers · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection
Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).
1 finding from 1 review